TY - JOUR
T1 - Pharmacokinetic evaluation of (-)-6-aminocarbovir as a prodrug for (-)-carbovir in rats
AU - Zimmerman, Cheryl L
AU - Remmel, Rory P
AU - Ibrahim, S. S.
AU - Beers, S. A.
AU - Vince, Robert
PY - 1992
Y1 - 1992
N2 - The recently synthesized carbocyclic 2',3'-didehydro-2',3'-dideoxy-6-deoxy-6-amino-guanosine [(-)6AC] was evaluated as a prodrug for carbovir, carbocyclic 2',3'-didehydro-2',3'-dideoxyguanosine [(-)CBV] in seven male Sprague-Dawley rats. A randomized three-way cross-over design was used. Rats were assigned to receive the following treatments: a 20 mg/kg (-)6AC infusion, 40 mg/kg (-)6AC orally, and a 20 mg/kg (-)CBV infusion. Blood samples were collected over 480 min, and urine was collected for up to 48 hr. A 2- to 3-day washout period was observed between treatments. Following iv infusion, (-)6AC concentrations in the blood declined rapidly in a monoexponential pattern with an elimination half-life of 11.3 ± 3.3 min (mean ± SD, n = 7). The time-averaged total body clearance was 115.7 ± 32.6 ml/min/kg. The fraction of the dose excreted unchanged in urine was 0.28 ± 0.06. The fraction of the (-)6AC dose metabolized to (-)CBV was 0.48 ± 0.14. Following oral administration of (-)6AC, the bioavailability of (-)CBV was 46.2 ± 9.9% (n = 6) in comparison with the bioavailability of approximately 20% previously obtained after an oral dose of (-)CBV. The C(max) of (-)CBV after a 40 mg/kg oral dose of (-)6AC was 1.65 ± 0.7 μg/ml as compared with the previously reported C(max) of 1.00 μg/ml obtained after a 60 mg/kg oral dose of (-)CBV. (-)6AC has considerable potential for the improvement of the extent of absorption of (-)CBV from oral dosing.
AB - The recently synthesized carbocyclic 2',3'-didehydro-2',3'-dideoxy-6-deoxy-6-amino-guanosine [(-)6AC] was evaluated as a prodrug for carbovir, carbocyclic 2',3'-didehydro-2',3'-dideoxyguanosine [(-)CBV] in seven male Sprague-Dawley rats. A randomized three-way cross-over design was used. Rats were assigned to receive the following treatments: a 20 mg/kg (-)6AC infusion, 40 mg/kg (-)6AC orally, and a 20 mg/kg (-)CBV infusion. Blood samples were collected over 480 min, and urine was collected for up to 48 hr. A 2- to 3-day washout period was observed between treatments. Following iv infusion, (-)6AC concentrations in the blood declined rapidly in a monoexponential pattern with an elimination half-life of 11.3 ± 3.3 min (mean ± SD, n = 7). The time-averaged total body clearance was 115.7 ± 32.6 ml/min/kg. The fraction of the dose excreted unchanged in urine was 0.28 ± 0.06. The fraction of the (-)6AC dose metabolized to (-)CBV was 0.48 ± 0.14. Following oral administration of (-)6AC, the bioavailability of (-)CBV was 46.2 ± 9.9% (n = 6) in comparison with the bioavailability of approximately 20% previously obtained after an oral dose of (-)CBV. The C(max) of (-)CBV after a 40 mg/kg oral dose of (-)6AC was 1.65 ± 0.7 μg/ml as compared with the previously reported C(max) of 1.00 μg/ml obtained after a 60 mg/kg oral dose of (-)CBV. (-)6AC has considerable potential for the improvement of the extent of absorption of (-)CBV from oral dosing.
UR - http://www.scopus.com/inward/record.url?scp=0026499919&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026499919&partnerID=8YFLogxK
M3 - Article
C2 - 1346995
AN - SCOPUS:0026499919
SN - 0090-9556
VL - 20
SP - 47
EP - 51
JO - Drug Metabolism and Disposition
JF - Drug Metabolism and Disposition
IS - 1
ER -